nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

20.05.2022 | Original Article

Dual Specific Phosphatase 7 Exacerbates Dilated Cardiomyopathy, Heart Failure, and Cardiac Death by Inactivating the ERK1/2 Signaling Pathway

verfasst von: Jing Liu, Yihen Yin, Jing Ni, Peiyu Zhang, Wei-ming Li, Zheng Liu

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Heart failure is one of the most common but complicated end-stage syndromes in clinical practice. Dilated cardiomyopathy is a myocardial structural abnormality that is associated with heart failure. Dual-specificity phosphatases (DUSPs) are a group of protein phosphatases that regulate signaling pathways in numerous diseases; however, their physiological and pathological impact on cardiovascular disease remains unknown. In the present study, we generated two transgenic mouse models, a DUSP7 knockout and a cardiac-specific DUSP7 overexpressor. Mice overexpressing DUSP7 showed an exacerbated disease phenotype, including severe dilated cardiomyopathy, heart failure, and cardiac death. We further demonstrated that high levels of DUSP7 inhibited ERK1/2 phosphorylation and influenced downstream c-MYC, c-FOS, and c-JUN gene expression but did not affect upstream activators. Taken together, our study reveals a novel molecular mechanism for DUSP7 and provides a new therapeutic target and clinical path to alleviate dilated cardiomyopathy and improve cardiac function.

Graphical abstract

Nur mit Berechtigung zugänglich

Bueno, H., Moura, B., Lancellotti, P., & Bauersachs, J. (2021). The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. European Heart Journal, 42(6), 657–670. https://doi.org/10.1093/eurheartj/ehaa1061CrossRef

Takagaki, K., Satoh, T., Tanuma, N., Masuda, K., Takekawa, M., Shima, H., et al. (2004). Characterization of a novel low-molecular-mass dual-specificity phosphatase-3 (LDP-3) that enhances activation of JNK and p38. Biochemical Journal,383(Pt. 3), 447–455. https://doi.org/10.1042/bj20040498CrossRef

Wang, J. Y., Lin, C. H., Yang, C. H., Tan, T. H., & Chen, Y. R. (2006). Biochemical and biological characterization of a neuroendocrine-associated phosphatase. Journal of Neurochemistry, 98(1), 89–101. https://doi.org/10.1111/j.1471-4159.2006.03852.xCrossRef

Li, W. M., Zhao, Y. F., Zhu, G. F., Peng, W. H., Zhu, M. Y., Yu, X. J., et al. (2017). Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload. Clinical Science(London), 131(2), 141–154. https://doi.org/10.1042/CS20160664CrossRef

Caunt, C. J., & Keyse, S. M. (2013). Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. FEBS Journal, 280(2), 489–504. https://doi.org/10.1111/j.1742-4658.2012.08716.xCrossRef

Xu, S., Furukawa, T., Kanai, N., Sunamura, M., & Horii, A. (2005). Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. Journal of Human Genetics, 50(4), 159–167. https://doi.org/10.1007/s10038-005-0235-yCrossRef

Liao, Q., Guo, J., Kleeff, J., Zimmermann, A., Büchler, M. W., Korc, M., et al. (2003). Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology, 124(7), 1830–1845. https://doi.org/10.1016/s0016-5085(03)00398-6CrossRef

Srikanth, S., Franklin, C. C., Duke, R. C., & Kraft, R. S. (1999). Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Molecular and Cellular Biochemistry, 199(1–2), 169–178. https://doi.org/10.1023/a:1006980326855CrossRef

Weber, R. G., Rieger, J., Naumann, U., Lichter, P., & Weller, M. (2001). Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma cell lines. International Journal of Cancer, 91(2), 213–218. https://doi.org/10.1002/1097-0215(200002)9999:9999%3c::aid-ijc1036%3e3.3.co;2-dCrossRef

10.

Bang, Y. J., Kwon, J. H., Kang, S. H., Kim, J. W., & Yang, Y. C. (1998). Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. Biochemical and Biophysical Research Communications, 250(1), 43–47. https://doi.org/10.1006/bbrc.1998.9256CrossRef

11.

Givant-Horwitz, V., Davidson, B., Goderstad, J. M., Nesland, J. M., Tropé, C. G., & Reich, R. (2004). The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecologic Oncology, 93(2), 517–523. https://doi.org/10.1016/j.ygyno.2004.03.009CrossRef

12.

Auger-Messier, M., Accornero, F., Goonasekera, S. A., Bueno, O. F., Lorenz, J. N., van Berlo, J. H., et al. (2013). Unrestrained p38 MAPK activation in Dusp1/4 double-null mice induces cardiomyopathy. Circulation Research, 112(1), 48–56. https://doi.org/10.1161/circresaha.112.272963CrossRef

13.

Maillet, M., Purcell, N. H., Sargent, M. A., York, A. J., Bueno, O. F., & Molkentin, J. D. (2008). DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility. Journal of Biological Chemistry, 283(45), 31246–31255. https://doi.org/10.1074/jbc.M806085200CrossRef

14.

Liu, R., van Berlo, J. H., York, A. J., Vagnozzi, R. J., Maillet, M., & Molkentin, J. D. (2016). DUSP8 Regulates Cardiac Ventricular Remodeling by Altering ERK1/2 Signaling. Circulation Research, 119(2), 249–260. https://doi.org/10.1161/circresaha.115.308238CrossRef

15.

Levy-Nissenbaum, O., Sagi-Assif, O., Raanani, P., Avigdor, A., Ben-Bassat, I., & Witz, I. P. (2003). Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukaemia. Cancer Letters, 199(2), 185–192. https://doi.org/10.1016/s0304-3835(03)00352-5CrossRef

16.

Urness, L. D., Li, C., Wang, X., & Mansour, S. L. (2008). Expression of ERK signaling inhibitors Dusp6, Dusp7, and Dusp9 during mouse ear development. Developmental Dynamics, 237(1), 163–169. https://doi.org/10.1002/dvdy.21380CrossRef

17.

Tischer, T., & Schuh, M. (2016). The phosphatase Dusp7 drives meiotic resumption and chromosome alignment in mouse oocytes. Cell Reports, 17(5), 1426–1437. https://doi.org/10.1016/j.celrep.2016.10.007CrossRef

18.

Singh, S., Koyalakonda, S. P., & Krishnan, U. (2011). Severe dilated cardiomyopathy resulting in a globular cardiac silhouette on chest X-ray. Journal of Echocardiography, 9(3), 123–124. https://doi.org/10.1007/s12574-010-0078-1CrossRef

19.

Badgett, R. G., Mulrow, C. D., Otto, P. M., & Ramírez, G. (1996). How well can the chest radiograph diagnose left ventricular dysfunction? Journal of General Internal Medicine, 11(10), 625–634. https://doi.org/10.1007/bf02599031CrossRef

20.

Organ, C. L., Otsuka, H., Bhushan, S., Wang, Z., Bradley, J., Trivedi, R., et al. (2016). Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure. Circulatory Heart Failure, 9(1), e002314. https://doi.org/10.1161/circheartfailure.115.002314CrossRef

21.

Makarewich, C. A., Munir, A. Z., Schiattarella, G. G., Bezprozvannaya, S., Raguimova, O. N., Cho, E. E., et al. (2018). The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy. Elife, 7. https://doi.org/10.7554/eLife.38319

22.

Pieske, B. (2004). Reverse remodeling in heart failure – fact or fiction? European Heart Journal Supplements, 6(suppl_D), D66–D78. https://doi.org/10.1016/j.ehjsup.2004.05.019CrossRef

23.

Teerlink, J. R., Pfeffer, J. M., & Pfeffer, M. A. (1994). Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circulation Research, 75(1), 105–113. https://doi.org/10.1161/01.res.75.1.105CrossRef

24.

The Gene Ontology resource: enriching a GOld mine (2021). Nucleic Acids Research, 49(D1), D325-D334, doi:https://doi.org/10.1093/nar/gkaa1113.

25.

Kanehisa, M., Araki, M., Goto, S., Hattori, M., Hirakawa, M., Itoh, M., et al. (2008). KEGG for linking genomes to life and the environment. Nucleic Acids Research, 36(Database issue), D480-484. https://doi.org/10.1093/nar/gkm882CrossRef

26.

Widyastuti, H. P., Norden-Krichmar, T. M., Grosberg, A., & Zaragoza, M. V. (2020). Gene expression profiling of fibroblasts in a family with LMNA-related cardiomyopathy reveals molecular pathways implicated in disease pathogenesis. BMC Medical Genomics, 21(1), 152. https://doi.org/10.1186/s12881-020-01088-wCrossRef

27.

Cipolletta, E., Rusciano, M. R., Maione, A. S., Santulli, G., Sorriento, D., Del Giudice, C., et al. (2015). Targeting the CaMKII/ERK interaction in the Heart prevents cardiac hypertrophy. PLoS One, 10(6), e0130477. https://doi.org/10.1371/journal.pone.0130477CrossRef

28.

Luczak, E. D., Wu, Y., Granger, J. M., Joiner, M. A., Wilson, N. R., Gupta, A., et al. (2020). Mitochondrial CaMKII causes adverse metabolic reprogramming and dilated cardiomyopathy. Nature Communications, 11(1), 4416. https://doi.org/10.1038/s41467-020-18165-6CrossRef

29.

Communal, C., Colucci, W. S., Remondino, A., Sawyer, D. B., Port, J. D., Wichman, S. E., et al. (2002). Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium. Journal of Cardiac Failure, 8(2), 86–92. https://doi.org/10.1054/jcaf.2002.32755CrossRef

30.

Newton, R., Shah, S., Altonsy, M. O., & Gerber, A. N. (2017). Glucocorticoid and cytokine crosstalk: Feedback, feedforward, and co-regulatory interactions determine repression or resistance. Journal of Biological Chemistry, 292(17), 7163–7172. https://doi.org/10.1074/jbc.R117.777318CrossRef

31.

Brion, L., Maloberti, P. M., Gomez, N. V., Poderoso, C., Gorostizaga, A. B., Mori Sequeiros Garcia, M. M., et al. (2011). MAPK phosphatase-1 (MKP-1) expression is up-regulated by hCG/cAMP and modulates steroidogenesis in MA-10 Leydig cells. Endocrinology, 152(7), 2665–2677. https://doi.org/10.1210/en.2011-0021CrossRef

32.

Lin, Y. W., & Yang, J. L. (2006). Cooperation of ERK and SCFSkp2 for MKP-1 destruction provides a positive feedback regulation of proliferating signaling. Journal of Biological Chemistry, 281(2), 915–926. https://doi.org/10.1074/jbc.M508720200CrossRef

33.

Nguyen, K. A., Intriago, R. E., Upadhyay, H. C., Santos, S. J., Webster, N. J., & Lawson, M. A. (2010). Modulation of gonadotropin-releasing hormone-induced extracellular signal-regulated kinase activation by dual-specificity protein phosphatase 1 in LbetaT2 gonadotropes. Endocrinology, 151(10), 4882–4893. https://doi.org/10.1210/en.2009-1483CrossRef

34.

Fuller, S. J., Davies, E. L., Gillespie-Brown, J., Sun, H., & Tonks, N. K. (1997). Mitogen-activated protein kinase phosphatase 1 inhibits the stimulation of gene expression by hypertrophic agonists in cardiac myocytes. Biochemical Journal, 323(Pt 2), 313–319. https://doi.org/10.1042/bj3230313CrossRef

35.

Cobb, M. H., & Goldsmith, E. J. (1995). How MAP kinases are regulated. Journal of Biological Chemistry, 270(25), 14843–14846. https://doi.org/10.1074/jbc.270.25.14843CrossRef

36.

Seger, R., Ahn, N. G., Posada, J., Munar, E. S., Jensen, A. M., Cooper, J. A., et al. (1992). Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. Journal of Biological Chemistry, 267(20), 14373–14381.CrossRef

37.

Zheng, C. F., & Guan, K. L. (1993). Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2. Journal of Biological Chemistry, 268(15), 11435–11439.CrossRef

38.

Matsubayashi, Y., Fukuda, M., & Nishida, E. (2001). Evidence for existence of a nuclear pore complex-mediated, cytosol-independent pathway of nuclear translocation of ERK MAP kinase in permeabilized cells. Journal of Biological Chemistry, 276(45), 41755–41760. https://doi.org/10.1074/jbc.M106012200CrossRef

39.

Khokhlatchev, A. V., Canagarajah, B., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E., et al. (1998). Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell, 93(4), 605–615. https://doi.org/10.1016/s0092-8674(00)81189-7CrossRef

40.

Maik-Rachline, G., Hacohen-Lev-Ran, A., & Seger, R. (2019). Nuclear ERK: Mechanism of translocation, substrates, and role in cancer. International Journal of Molecular Sciences, 20(5), doi:https://doi.org/10.3390/ijms20051194.

41.

Brunet, A., Roux, D., Lenormand, P., Dowd, S., Keyse, S., & Pouysségur, J. (1999). Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. The EMBO Journal, 18(3), 664–674. https://doi.org/10.1093/emboj/18.3.664CrossRef

42.

Bueno, O. F., De Windt, L. J., Tymitz, K. M., Witt, S. A., Kimball, T. R., Klevitsky, R., et al. (2000). The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. The EMBO Journal, 19(23), 6341–6350. https://doi.org/10.1093/emboj/19.23.6341CrossRef

43.

Lorenz, K., Schmitt, J. P., Schmitteckert, E. M., & Lohse, M. J. (2009). A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Natural Medicines, 15(1), 75–83. https://doi.org/10.1038/nm.1893CrossRef

44.

Purcell, N. H., Wilkins, B. J., York, A., Saba-El-Leil, M. K., Meloche, S., Robbins, J., et al. (2007). Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proceedings of the National Academy of Sciences of the United States of America, 104(35), 14074–14079. https://doi.org/10.1073/pnas.0610906104CrossRef

45.

Flesch, M., Margulies, K. B., Mochmann, H. C., Engel, D., Sivasubramanian, N., & Mann, D. L. (2001). Differential regulation of mitogen-activated protein kinases in the failing human heart in response to mechanical unloading. Circulation, 104(19), 2273–2276. https://doi.org/10.1161/hc4401.099449CrossRef

46.

Xiao, L., Pimental, D. R., Amin, J. K., Singh, K., Sawyer, D. B., & Colucci, W. S. (2001). MEK1/2-ERK1/2 mediates alpha1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. Journal of Molecular and Cellular Cardiology, 33(4), 779–787. https://doi.org/10.1006/jmcc.2001.1348CrossRef

47.

Du, J., Guan, T., Zhang, H., Xia, Y., Liu, F., & Zhang, Y. (2008). Inhibitory crosstalk between ERK and AMPK in the growth and proliferation of cardiac fibroblasts. Biochemical and Biophysical Research Communications, 368(2), 402–407. https://doi.org/10.1016/j.bbrc.2008.01.099CrossRef

48.

Kontaridis, M. I., Yang, W., Bence, K. K., Cullen, D., Wang, B., Bodyak, N., et al. (2008). Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways. Circulation, 117(11), 1423–1435. https://doi.org/10.1161/circulationaha.107.728865CrossRef

49.

Dzimiri, N., Al-Bahnasi, K., & Al-Halees, Z. (2004). Myocardial hypertrophy is not a prerequisite for changes in early gene expression in left ventricular volume overload. Fundamental & Clinical Pharmacology, 18(1), 39–44. https://doi.org/10.1046/j.0767-3981.2003.00212.xCrossRef

50.

Fried, L. E., & Arbiser, J. L. (2009). Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxidants & Redox Signaling, 11(5), 1139–1148. https://doi.org/10.1089/ars.2009.2440CrossRef

51.

Chi, Z., Le, T. P. H., Lee, S. K., Guo, E., Kim, D., Lee, S., et al. (2020). Honokiol ameliorates angiotensin II-induced hypertension and endothelial dysfunction by inhibiting HDAC6-mediated cystathionine γ-lyase degradation. Journal of Cellular and Molecular Medicine, 24(18), 10663–10676. https://doi.org/10.1111/jcmm.15686CrossRef

52.

Pillai, V. B., Samant, S., Sundaresan, N. R., Raghuraman, H., Kim, G., Bonner, M. Y., et al. (2015). Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nature Communications, 6, 6656. https://doi.org/10.1038/ncomms7656CrossRef

53.

Tan, Z., Liu, H., Song, X., Ling, Y., He, S., Yan, Y., et al. (2019). Honokiol post-treatment ameliorates myocardial ischemia/reperfusion injury by enhancing autophagic flux and reducing intracellular ROS production. Chemico-Biological Interactions, 307, 82–90. https://doi.org/10.1016/j.cbi.2019.04.032CrossRef

54.

Zhang, B., Zhai, M., Li, B., Liu, Z., Li, K., Jiang, L., et al. (2018). Honokiol ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by reducing oxidative stress and apoptosis through activating the SIRT1-Nrf2 signaling pathway. Oxidative Medicine and Cellular Longevity, 2018, 3159801. https://doi.org/10.1155/2018/3159801CrossRef

55.

Wei, X. Q., Zhang, H. S., Wei, G. H., Zhang, J. G., Du, Y. Y., Tan, H. Y., et al. (2018). Honokiol protects against anti-β1-adrenergic receptor autoantibody-induced myocardial dysfunction via activation of autophagy. Oxidative Medicine and Cellular Longevity, 2018, 1640804. https://doi.org/10.1155/2018/1640804CrossRef

56.

Tsai, S. K., Huang, S. S., & Hong, C. Y. (1996). Myocardial protective effect of honokiol: an active component in Magnolia officinalis. Planta Medica, 62(6), 503–506. https://doi.org/10.1055/s-2006-957957CrossRef

57.

Tsai, S. K., Huang, C. H., Huang, S. S., Hung, L. M., & Hong, C. Y. (1999). Antiarrhythmic effect of magnolol and honokiol during acute phase of coronary occlusion in anesthetized rats: influence of L-NAME and aspirin. Pharmacology, 59(5), 227–233. https://doi.org/10.1159/000028324CrossRef

58.

Zhai, H., Nakade, K., Oda, M., Mitsumoto, Y., Akagi, M., Sakurai, J., et al. (2005). Honokiol-induced neurite outgrowth promotion depends on activation of extracellular signal-regulated kinases (ERK1/2). European Journal of Pharmacology, 516(2), 112–117. https://doi.org/10.1016/j.ejphar.2005.04.035CrossRef

59.

Huang, K., Chen, Y., Zhang, R., Wu, Y., Ma, Y., Fang, X., et al. (2018). Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo. Cell Death & Disease, 9(2), 157. https://doi.org/10.1038/s41419-017-0166-5CrossRef

60.

Peng, X., Li, X., Li, C., Yue, S., Huang, Y., Huang, P., et al. (2019). NMDA receptor activation inhibits the protective effect of BM-MSCs on bleomycin-induced lung epithelial cell damage by inhibiting ERK signaling and the paracrine factor HGF. International Journal of Molecular Medicine, 44(1), 227–239. https://doi.org/10.3892/ijmm.2019.4195CrossRef

61.

Wang, J., Yang, H., Li, Q., Wu, X., Di, G., Fan, J., et al. (2020). Novel nanomicelles based on rebaudioside A: A potential nanoplatform for oral delivery of honokiol with enhanced oral bioavailability and antitumor activity. International Journal of Pharmaceutics, 590, 119899. https://doi.org/10.1016/j.ijpharm.2020.119899CrossRef

62.

Pillai, V. B., Kanwal, A., Fang, Y. H., Sharp, W. W., Samant, S., Arbiser, J., et al. (2017). Honokiol, an activator of sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. Oncotarget, 8(21), 34082–34098. https://doi.org/10.18632/oncotarget.16133CrossRef

63.

Wu, L., Liu, Y., Zhao, Y., Li, M., & Guo, L. (2020). Targeting DUSP7 signaling alleviates hepatic steatosis, inflammation and oxidative stress in high fat diet (HFD)-fed mice via suppression of TAK1. Free Radical Biology & Medicine, 153, 140–158. https://doi.org/10.1016/j.freeradbiomed.2020.04.009CrossRef

64.

Zeng, C., Liang, B., Jiang, R., Shi, Y., & Du, Y. (2017). Protein kinase C isozyme expression in right ventricular hypertrophy induced by pulmonary hypertension in chronically hypoxic rats. Molecular Medicine Reports, 16(4), 3833–3840. https://doi.org/10.3892/mmr.2017.7098CrossRef

65.

Zhao, J., Jiang, X., Liu, J., Ye, P., Jiang, L., Chen, M., et al. (2021). Dual-specificity phosphatase 26 protects against cardiac hypertrophy through TAK1. Journal of the American Heart Association, 10(4), e014311. https://doi.org/10.1161/jaha.119.014311CrossRef

66.

Reiter, E., Ahn, S., Shukla, A. K., & Lefkowitz, R. J. (2012). Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annual Review of Pharmacology and Toxicology, 52(1), 179–197. https://doi.org/10.1146/annurev.pharmtox.010909.105800CrossRef

67.

Gallo, S., Vitacolonna, A., Bonzano, A., Comoglio, P., & Crepaldi, T. (2019). ERK: A key player in the pathophysiology of cardiac hypertrophy. International Journal of Molecular Sciences, 20(9), 2164. https://doi.org/10.3390/ijms20092164CrossRef

68.

DeFea, K. A., Zalevsky, J., Thoma, M. S., Déry, O., Mullins, R. D., & Bunnett, N. W. (2000). β-Arrestin–dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated Erk1/2. Journal of Cell Biology, 148(6), 1267–1282. https://doi.org/10.1083/jcb.148.6.1267CrossRef

69.

Kehat, I., Davis, J., Tiburcy, M., Accornero, F., Saba-El-Leil, M. K., Maillet, M., et al. (2011). Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circulation Research, 108(2), 176–183. https://doi.org/10.1161/circresaha.110.231514CrossRef

70.

Schnelle, M., Sawyer, I., Anilkumar, N., Mohamed, B. A., Richards, D. A., Toischer, K., et al. (2021). NADPH oxidase-4 promotes eccentric cardiac hypertrophy in response to volume overload. Cardiovascular Research, 117(1), 178–187. https://doi.org/10.1093/cvr/cvz331CrossRef

71.

Barry, S. P., & Townsend, P. A. (2010). What causes a broken heart–molecular insights into heart failure. International Review of Cell and Molecular Biology, 284, 113–179. https://doi.org/10.1016/s1937-6448(10)84003-1CrossRef

72.

Monje, P., Marinissen, M. J., & Gutkind, J. S. (2003). Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor. Molecular and Cellular Biology, 23(19), 7030–7043. https://doi.org/10.1128/mcb.23.19.7030-7043.2003CrossRef

73.

Kami, D., Kitani, T., Kawasaki, T., & Gojo, S. (2016). Cardiac mesenchymal progenitors differentiate into adipocytes via Klf4 and c-Myc. Cell Death & Disease, 7(4), e2190. https://doi.org/10.1038/cddis.2016.31CrossRef

74.

Shaulian, E., & Karin, M. (2002). AP-1 as a regulator of cell life and death. Nature Cell Biology, 4(5), E131-136. https://doi.org/10.1038/ncb0502-e131CrossRef

75.

Shaulian, E. (2010). AP-1–The Jun proteins: Oncogenes or tumor suppressors in disguise? Cellular Signalling, 22(6), 894–899. https://doi.org/10.1016/j.cellsig.2009.12.008CrossRef

76.

Vesely, P. W., Staber, P. B., Hoefler, G., & Kenner, L. (2009). Translational regulation mechanisms of AP-1 proteins. Mutation Research, 682(1), 7–12. https://doi.org/10.1016/j.mrrev.2009.01.001CrossRef

77.

Barrans, J. D., Allen, P. D., Stamatiou, D., Dzau, V. J., & Liew, C. C. (2002). Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. The American Journal of Pathology, 160(6), 2035–2043. https://doi.org/10.1016/s0002-9440(10)61153-4CrossRef

78.

Schunkert, H., Jahn, L., Izumo, S., Apstein, C. S., & Lorell, B. H. (1991). Localization and regulation of c-fos and c-jun protooncogene induction by systolic wall stress in normal and hypertrophied rat hearts. Proceedings of the National Academy of Sciences of the United States of America, 88(24), 11480–11484. https://doi.org/10.1073/pnas.88.24.11480CrossRef

79.

Monje, P., Hernández-Losa, J., Lyons, R. J., Castellone, M. D., & Gutkind, J. S. (2005). Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. The Journal of Biological Chemistry, 280(42), 35081–35084. https://doi.org/10.1074/jbc.C500353200CrossRef

80.

Singal, T., Dhalla, N. S., & Tappia, P. S. (2009). Regulation of c-Fos and c-Jun gene expression by phospholipase C activity in adult cardiomyocytes. Molecular and Cellular Biology, 327(1–2), 229–239. https://doi.org/10.1007/s11010-009-0061-1CrossRef

81.

Omura, T., Yoshiyama, M., Yoshida, K., Nakamura, Y., Kim, S., Iwao, H., et al. (2002). Dominant negative mutant of c-Jun inhibits cardiomyocyte hypertrophy induced by endothelin 1 and phenylephrine. Hypertension, 39(1), 81–86. https://doi.org/10.1161/hy0102.100783CrossRef

82.

Starksen, N. F., Simpson, P. C., Bishopric, N., Coughlin, S. R., Lee, W. M., Escobedo, J. A., et al. (1986). Cardiac myocyte hypertrophy is associated with c-myc protooncogene expression. Proceedings of the National Academy of Sciences of the United States of America, 83(21), 8348–8350. https://doi.org/10.1073/pnas.83.21.8348CrossRef

83.

Jackson, T., Allard, M. F., Sreenan, C. M., Doss, L. K., Bishop, S. P., & Swain, J. L. (1990). The c-myc proto-oncogene regulates cardiac development in transgenic mice. Molecular and Cellular Biology, 10(7), 3709–3716. https://doi.org/10.1128/mcb.10.7.3709CrossRef

84.

Willis, M. S., Holley, D. W., Wang, Z., Chen, X., Quintana, M., Jensen, B. C., et al. (2017). BRG1 and BRM function antagonistically with c-MYC in adult cardiomyocytes to regulate conduction and contractility. Journal of Molecular and Cellular Cardiology, 105, 99–109. https://doi.org/10.1016/j.yjmcc.2017.02.003CrossRef

85.

Xiao, G., Mao, S., Baumgarten, G., Serrano, J., Jordan, M. C., Roos, K. P., et al. (2001). Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis. Circulation Research, 89(12), 1122–1129. https://doi.org/10.1161/hh2401.100742CrossRef

86.

Hou, N., Ye, B., Li, X., Margulies, K. B., Xu, H., Wang, X., et al. (2016). Transcription factor 7-like 2 mediates canonical Wnt/β-catenin signaling and c-Myc upregulation in heart failure. Circulation. Heart Failure, 9(6), doi:https://doi.org/10.1161/circheartfailure.116.003010.

87.

Gawdzik, J. C., Yue, M. S., Martin, N. R., Elemans, L. M. H., Lanham, K. A., Heideman, W., et al. (2018). sox9b is required in cardiomyocytes for cardiac morphogenesis and function. Scientific Reports, 8(1), 13906. https://doi.org/10.1038/s41598-018-32125-7CrossRef

88.

Brown, S. M., Smith, C. E., Meuth, A. I., Khan, M., Aroor, A. R., Cleeton, H. M., et al. (2017). Dipeptidyl peptidase-4 inhibition with saxagliptin ameliorates angiotensin II-induced cardiac diastolic dysfunction in male mice. Endocrinology, 158(10), 3592–3604. https://doi.org/10.1210/en.2017-00416CrossRef

Titel: Dual Specific Phosphatase 7 Exacerbates Dilated Cardiomyopathy, Heart Failure, and Cardiac Death by Inactivating the ERK1/2 Signaling Pathway
verfasst von: Jing Liu
Yihen Yin
Jing Ni
Peiyu Zhang
Wei-ming Li
Zheng Liu
Publikationsdatum: 20.05.2022
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 6/2022
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-022-10268-3

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Dual Specific Phosphatase 7 Exacerbates Dilated Cardiomyopathy, Heart Failure, and Cardiac Death by Inactivating the ERK1/2 Signaling Pathway

Abstract

Graphical abstract

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

TJ-M2010-5 Attenuates Severe Myocardial Ischemia/Reperfusion Injury in Heart Transplantation by Inhibiting MyD88 Homodimerization In Vivo

CD137-CD137L Aggravates Calcification of Vascular Smooth Muscle Cell and Vasculature of ApoE−/− Mice Via Rab7-Mediated Autophagy

Impact of Myocardial Fibrosis on Cardiovascular Structure, Function and Functional Status in Heart Failure with Preserved Ejection Fraction

LncRNA HDAC11-AS1 Suppresses Atherosclerosis by Inhibiting HDAC11-Mediated Adropin Histone Deacetylation

Cardiac Electrophysiological Changes and Downregulated Connexin 43 Prompts Reperfusion Arrhythmias Induced by Hypothermic Ischemia–Reperfusion Injury in Isolated Rat Hearts

Serum miRNA-203 as a Novel Biomarker for the Early Prediction of Acute ST-elevation Myocardial Infarction

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie